17 alpha-hydroxylase deficiency differential diagnosis: Difference between revisions
Iqra Qamar (talk | contribs) |
|||
(24 intermediate revisions by 4 users not shown) | |||
Line 4: | Line 4: | ||
{{CMG}}; {{AE}} {{MJ}} | {{CMG}}; {{AE}} {{MJ}} | ||
==Overview== | ==Overview== | ||
17 alpha-hydroxylase deficiency must be differentiated from diseases with [[primary amenorrhea]] and female [[external genitalia]] | 17 alpha-hydroxylase deficiency must be differentiated from diseases that present with [[primary amenorrhea]] and female [[external genitalia]] such as [[pregnancy]], [[androgen insensitivity syndrome]], 3beta-hydroxysteroid dehydrogenase type 2 deficiency, gonadal dysgenesis, [[testicular regression syndrome]], [[LH receptor|LH receptor defects]], [[5-alpha-reductase deficiency|5-alpha-reductase type 2 deficiency]], [[mullerian agenesis]], [[Ovarian insufficiency|primary ovarian insufficiency]], [[hypogonadotropic hypogonadism]] and [[turner syndrome]]. | ||
==Differentiating 17 alpha-hydroxylase deficiency from other Diseases== | ==Differentiating 17 alpha-hydroxylase deficiency from other Diseases== | ||
17 alpha-hydroxylase deficiency must be differentiated from diseases with [[primary amenorrhea]] and female [[external genitalia]] | 17 alpha-hydroxylase deficiency must be differentiated from diseases that present with [[primary amenorrhea]] and female [[external genitalia]] such as [[pregnancy]], [[androgen insensitivity syndrome]], 3beta-hydroxysteroid dehydrogenase type 2 deficiency, gonadal dysgenesis, [[testicular regression syndrome]], [[LH receptor|LH receptor defects]], [[5-alpha-reductase deficiency|5-alpha-reductase type 2 deficiency]], [[mullerian agenesis]], [[Ovarian insufficiency|primary ovarian insufficiency]], [[hypogonadotropic hypogonadism]] and [[turner syndrome]]. | ||
.<ref name="pmid21147889">{{cite journal |vauthors=Maimoun L, Philibert P, Cammas B, Audran F, Bouchard P, Fenichel P, Cartigny M, Pienkowski C, Polak M, Skordis N, Mazen I, Ocal G, Berberoglu M, Reynaud R, Baumann C, Cabrol S, Simon D, Kayemba-Kay's K, De Kerdanet M, Kurtz F, Leheup B, Heinrichs C, Tenoutasse S, Van Vliet G, Grüters A, Eunice M, Ammini AC, Hafez M, Hochberg Z, Einaudi S, Al Mawlawi H, Nuñez CJ, Servant N, Lumbroso S, Paris F, Sultan C |title=Phenotypical, biological, and molecular heterogeneity of 5α-reductase deficiency: an extensive international experience of 55 patients |journal=J. Clin. Endocrinol. Metab. |volume=96 |issue=2 |pages=296–307 |year=2011 |pmid=21147889 |doi=10.1210/jc.2010-1024 |url=}}</ref><ref name="pmid2164530">{{cite journal |vauthors=Moreira AC, Leal AM, Castro M |title=Characterization of adrenocorticotropin secretion in a patient with 17 alpha-hydroxylase deficiency |journal=J. Clin. Endocrinol. Metab. |volume=71 |issue=1 |pages=86–91 |year=1990 |pmid=2164530 |doi=10.1210/jcem-71-1-86 |url=}}</ref><ref name="pmid999330">{{cite journal |vauthors=Heremans GF, Moolenaar AJ, van Gelderen HH |title=Female phenotype in a male child due to 17-alpha-hydroxylase deficiency |journal=Arch. Dis. Child. |volume=51 |issue=9 |pages=721–3 |year=1976 |pmid=999330 |pmc=1546244 |doi= |url=}}</ref><ref name="pmid226795">{{cite journal |vauthors=Biglieri EG |title=Mechanisms establishing the mineralocorticoid hormone patterns in the 17 alpha-hydroxylase deficiency syndrome |journal=J. Steroid Biochem. |volume=11 |issue=1B |pages=653–7 |year=1979 |pmid=226795 |doi= |url=}}</ref><ref name="pmid8929268">{{cite journal |vauthors=Saenger P |title=Turner's syndrome |journal=N. Engl. J. Med. |volume=335 |issue=23 |pages=1749–54 |year=1996 |pmid=8929268 |doi=10.1056/NEJM199612053352307 |url=}}</ref><ref name="pmid25813279">{{cite journal |vauthors=Bastian C, Muller JB, Lortat-Jacob S, Nihoul-Fékété C, Bignon-Topalovic J, McElreavey K, Bashamboo A, Brauner R |title=Genetic mutations and somatic anomalies in association with 46,XY gonadal dysgenesis |journal=Fertil. Steril. |volume=103 |issue=5 |pages=1297–304 |year=2015 |pmid=25813279 |doi=10.1016/j.fertnstert.2015.01.043 |url=}}</ref><ref name="pmid4432067">{{cite journal |vauthors=Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE |title=Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism |journal=Science |volume=186 |issue=4170 |pages=1213–5 |year=1974 |pmid=4432067 |doi= |url=}}</ref><ref name="pmid11344932">{{cite journal |vauthors=Schnitzer JJ, Donahoe PK |title=Surgical treatment of congenital adrenal hyperplasia |journal=Endocrinol. Metab. Clin. North Am. |volume=30 |issue=1 |pages=137–54 |year=2001 |pmid=11344932 |doi= |url=}}</ref> | |||
=== Differential diagnosis for [[primary amenorrhea]]: === | |||
{| class="wikitable" | {| class="wikitable" | ||
|- | |- | ||
! rowspan="2" | Disease name | ! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + | Disease name | ||
! rowspan="2" | Cause | ! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + | Cause | ||
! colspan="7" | Differentiating | ! colspan="7" style="background:#4479BA; color: #FFFFFF;" + | Differentiating | ||
|- | |- | ||
!Findings | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Findings | ||
! | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Uterus | ||
! | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Breast development | ||
! | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Testosterone | ||
! | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |LH | ||
! | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |FSH | ||
! | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Karyotyping | ||
|- | |- | ||
![[17-alpha-hydroxylase deficiency]] | |||
| | | | ||
* | * [[CYP17A1|CYP17A1 gene mutation]] | ||
| | | | ||
* [[ | * Female [[external genitalia]] | ||
* | |||
* [[Primary amenorrhea]] | |||
* [[Hypertension]] | |||
* Absence of secondary [[sexual characteristics]] | |||
* Minimal [[body hair]] | |||
| align="center" style="padding: 5px 5px; background: " | | | align="center" style="padding: 5px 5px; background: " | | ||
No | |||
| align="center" style="padding: 5px 5px; background: " | | | align="center" style="padding: 5px 5px; background: " | | ||
No | |||
| align="center" style="padding: 5px 5px; background: " | | | align="center" style="padding: 5px 5px; background: " | | ||
↓ | |||
| align="center" style="padding: 5px 5px; background: " | | | align="center" style="padding: 5px 5px; background: " | | ||
Normal | Normal | ||
| align="center" style="padding: 5px 5px; background: " | | | align="center" style="padding: 5px 5px; background: " | | ||
Normal | Normal | ||
|align="center" style="padding: 5px 5px; background: " | | | align="center" style="padding: 5px 5px; background: " | | ||
[[XY | [[XY]] | ||
|- | |- | ||
![[3 beta-hydroxysteroid dehydrogenase deficiency]] | |||
| | | | ||
* [[ | * HSD3B2 [[gene]] [[mutation]] | ||
| | | | ||
* | * [[Undervirilization]] in 46,XY individuals due to a block in [[testosterone]] biosynthesis | ||
* Mild [[virilization]] in 46,XX individuals | |||
* | |||
| align="center" style="padding: 5px 5px; background: " | | | align="center" style="padding: 5px 5px; background: " | | ||
Yes in [[female]] | |||
| align="center" style="padding: 5px 5px; background: " | | | align="center" style="padding: 5px 5px; background: " | | ||
Yes in [[female]] | |||
| align="center" style="padding: 5px 5px; background: " | | | align="center" style="padding: 5px 5px; background: " | | ||
↓ | |||
| align="center" style="padding: 5px 5px; background: " | | | align="center" style="padding: 5px 5px; background: " | | ||
Normal | Normal | ||
Line 64: | Line 65: | ||
Normal | Normal | ||
| align="center" style="padding: 5px 5px; background: " | | | align="center" style="padding: 5px 5px; background: " | | ||
[[XY]] | [[XY]] and [[XX]] | ||
|- | |- | ||
![[Gonadal dysgenesis]] | |||
| | | | ||
* Mutations in [[SRY]], FOG2/ZFPM2, and WNT1 | * Mutations in [[SRY]], FOG2/ZFPM2, and WNT1 | ||
Line 72: | Line 73: | ||
* Female [[external genitalia]] | * Female [[external genitalia]] | ||
* Intact [[Mullerian ducts]] | * Intact [[Mullerian ducts]] | ||
* [[ | * Streak [[gonads]] | ||
| align="center" style="padding: 5px 5px; background: " | | | align="center" style="padding: 5px 5px; background: " | | ||
Yes | Yes | ||
Line 79: | Line 79: | ||
Yes | Yes | ||
| align="center" style="padding: 5px 5px; background: " | | | align="center" style="padding: 5px 5px; background: " | | ||
↓ | |||
| align="center" style="padding: 5px 5px; background: " | | | align="center" style="padding: 5px 5px; background: " | | ||
↑ | |||
| align="center" style="padding: 5px 5px; background: " | | | align="center" style="padding: 5px 5px; background: " | | ||
↑ | |||
| align="center" style="padding: 5px 5px; background: " | | | align="center" style="padding: 5px 5px; background: " | | ||
[[XY]] | [[XY]] | ||
|- | |- | ||
![[Testicular regression syndrome]] | |||
| | | | ||
* Loss of [[testicular]] function and tissue early in development | * Loss of [[testicular]] function and tissue early in development | ||
| | | | ||
* Female phenotype with atrophic [[Mullerian ducts]] | * Female phenotype with atrophic [[Mullerian ducts]] | ||
| align="center" style="padding: 5px 5px; background: " | | | align="center" style="padding: 5px 5px; background: " | | ||
No | No | ||
Line 97: | Line 97: | ||
No | No | ||
| align="center" style="padding: 5px 5px; background: " | | | align="center" style="padding: 5px 5px; background: " | | ||
↓ | |||
| align="center" style="padding: 5px 5px; background: " | | | align="center" style="padding: 5px 5px; background: " | | ||
↑ | |||
| align="center" style="padding: 5px 5px; background: " | | | align="center" style="padding: 5px 5px; background: " | | ||
↑ | |||
| align="center" style="padding: 5px 5px; background: " | | | align="center" style="padding: 5px 5px; background: " | | ||
[[XY]] | [[XY]] | ||
|- | |- | ||
![[LH receptor|LH receptor defects]] | |||
| | | | ||
* [[LH receptor]] [[gene]] [[mutation]] on [[chromosome 2]] | * [[LH receptor]] [[gene]] [[mutation]] on [[chromosome 2]] | ||
Line 114: | Line 114: | ||
* Laboratory: | * Laboratory: | ||
** Unresponsiveness to [[hCG]] | ** Unresponsiveness to [[hCG]] | ||
** Normal levels of [[testosterone]] precursors (produced in the [[adrenal glands]]) | ** Normal levels of [[testosterone]] precursors (produced in the [[adrenal glands]]) | ||
| align="center" style="padding: 5px 5px; background: " | | | align="center" style="padding: 5px 5px; background: " | | ||
No | No | ||
Line 120: | Line 120: | ||
No | No | ||
| align="center" style="padding: 5px 5px; background: " | | | align="center" style="padding: 5px 5px; background: " | | ||
↓ | |||
| align="center" style="padding: 5px 5px; background: " | | | align="center" style="padding: 5px 5px; background: " | | ||
↑ | |||
| align="center" style="padding: 5px 5px; background: " | | | align="center" style="padding: 5px 5px; background: " | | ||
↑ | |||
| align="center" style="padding: 5px 5px; background: " | | | align="center" style="padding: 5px 5px; background: " | | ||
[[XY]] | [[XY]] | ||
|- | |- | ||
![[5-alpha-reductase deficiency|5-alpha-reductase type 2 deficiency]] | |||
| | | | ||
* [[Autosomal recessive]] | * [[Autosomal recessive]] | ||
Line 136: | Line 136: | ||
* Impaired external [[virilization]] during [[embryogenesis]] | * Impaired external [[virilization]] during [[embryogenesis]] | ||
* Defective conversion of [[testosterone]] to [[DHT]] | * Defective conversion of [[testosterone]] to [[DHT]] | ||
* [[Testosterone]]:[[DHT]] ratio is >10:1 | * [[Testosterone]]:[[DHT]] ratio is >10:1 | ||
| align="center" style="padding: 5px 5px; background: " | | | align="center" style="padding: 5px 5px; background: " | | ||
Line 151: | Line 151: | ||
[[XY]] | [[XY]] | ||
|- | |- | ||
![[Androgen insensitivity syndrome]] | |||
| | | | ||
* [[Androgen receptor]] defect | * [[Androgen receptor]] defect | ||
Line 167: | Line 167: | ||
| align="center" style="padding: 5px 5px; background: " | | | align="center" style="padding: 5px 5px; background: " | | ||
Normal | Normal | ||
|align="center" style="padding: 5px 5px; background: " | | | align="center" style="padding: 5px 5px; background: " | | ||
[[XY]] | [[XY]] | ||
|- | |- | ||
![[Mullerian agenesis]] | |||
| | | | ||
* Mutations in ''[[WNT4]]'' | * Mutations in ''[[WNT4]]'' | ||
Line 189: | Line 189: | ||
[[XX]] | [[XX]] | ||
|- | |- | ||
![[Ovarian insufficiency|Primary ovarian insufficiency]] | |||
| | | | ||
* [[Genetic defects]] such as [[turner syndrome]], [[fragile X syndrome]], some other chromosomal defects | * [[Genetic defects]] such as [[turner syndrome]], [[fragile X syndrome]], some other chromosomal defects | ||
Line 201: | Line 201: | ||
Normal female range | Normal female range | ||
| align="center" style="padding: 5px 5px; background: " | | | align="center" style="padding: 5px 5px; background: " | | ||
↑ | |||
| align="center" style="padding: 5px 5px; background: " | | | align="center" style="padding: 5px 5px; background: " | | ||
↑ | |||
| align="center" style="padding: 5px 5px; background: " | | | align="center" style="padding: 5px 5px; background: " | | ||
[[XX]] | [[XX]] | ||
|- | |- | ||
![[Hypogonadotropic hypogonadism]] | |||
| | | | ||
* Functional, sellar masses | * Functional, sellar masses | ||
| | | | ||
* Normal [[female genitalia]] | * Normal [[female genitalia]] | ||
* Delayed [[puberty]] | * Delayed [[puberty]] | ||
Line 227: | Line 227: | ||
[[XX]] | [[XX]] | ||
|- | |- | ||
! align="center" style="padding: 5px 5px; background: " | | |||
[[Turner syndrome]] | [[Turner syndrome]] | ||
| | | | ||
* Chromosomal | * Chromosomal | ||
| | | | ||
* | * Normal female [[external genitalia]] | ||
| align="center" style="padding: 5px 5px; background: " | | | align="center" style="padding: 5px 5px; background: " | | ||
Yes | Yes | ||
Line 240: | Line 240: | ||
Normal [[female]] range | Normal [[female]] range | ||
| align="center" style="padding: 5px 5px; background: " | | | align="center" style="padding: 5px 5px; background: " | | ||
↑ | |||
| align="center" style="padding: 5px 5px; background: " | | |||
↑ | |||
| align="center" style="padding: 5px 5px; background: " | | | align="center" style="padding: 5px 5px; background: " | | ||
[[Turner syndrome|45 XO]] | [[Turner syndrome|45 XO]] | ||
|} | |||
===17 alpha-hydroxylase deficiency must be differentiated from diseases that cause [[ambiguous genitalia]]:<ref name="pmid17875484">{{cite journal |vauthors=Hughes IA, Nihoul-Fékété C, Thomas B, Cohen-Kettenis PT |title=Consequences of the ESPE/LWPES guidelines for diagnosis and treatment of disorders of sex development |journal=Best Pract. Res. Clin. Endocrinol. Metab. |volume=21 |issue=3 |pages=351–65 |year=2007 |pmid=17875484 |doi=10.1016/j.beem.2007.06.003 |url=}}</ref><ref name="pmid10857554">{{cite journal |vauthors=White PC, Speiser PW |title=Congenital adrenal hyperplasia due to 21-hydroxylase deficiency |journal=Endocr. Rev. |volume=21 |issue=3 |pages=245–91 |year=2000 |pmid=10857554 |doi=10.1210/edrv.21.3.0398 |url=}}</ref>=== | |||
{| class="wikitable" | |||
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease name | |||
! colspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Steroid status | |||
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Important clinical findings | |||
|- | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Increased | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Decreased | |||
|- | |||
![[17 alpha-hydroxylase deficiency|17-α hydroxylase deficiency]] | |||
| | |||
* [[Deoxycorticosterone]] | |||
* [[Corticosterone]] | |||
* [[Progesterone]] | |||
| | |||
* [[Cortisol]] | |||
* [[Aldosterone]] | |||
| | |||
* [[Ambiguous genitalia]] in male | |||
* [[Hypertension]] | |||
* [[Primary amenorrhea]] | |||
* Absence of [[secondary sexual characteristics]] | |||
* Minimal [[body hair]] | |||
|- | |||
![[21-hydroxylase deficiency|Classic type of 21-hydroxylase deficiency]] | |||
| | |||
* [[17-Hydroxyprogesterone|17-hydroxyprogesterone]] | |||
* [[Progesterone]] | |||
* [[Androstenedione]] | |||
* [[DHEA]] | |||
| | |||
* [[Aldosterone]] | |||
* [[Corticosterone]] (salt-wasting) | |||
* [[Cortisol]] ([[virilization]]) | |||
| | |||
* [[Ambiguous genitalia]] in female | |||
* [[Virilization]] in female | |||
* Salt-wasting | |||
* [[Hypotension]] and [[hyperkalemia]] | |||
|- | |||
![[11β-hydroxylase deficiency|11-β hydroxylase deficiency]] | |||
| | |||
* [[Deoxycorticosterone]] | |||
* 11-Deoxy-[[cortisol]] | |||
* [[17-Hydroxyprogesterone|17-hydroxyprogesterone]] (mild elevation) | |||
| | |||
* [[Cortisol]] | |||
* [[Corticosterone]] | |||
* [[Aldosterone]] | |||
| | |||
* [[Ambiguous genitalia]] in female | |||
* [[Hypertension]] and [[hypokalemia]] | |||
* [[Virilization]] | |||
|- | |||
![[3 beta-hydroxysteroid dehydrogenase deficiency]] | |||
| | |||
* [[Dehydroepiandrosterone]] | |||
* [[17-hydroxypregnenolone]] | |||
* [[Pregnenolone]] | |||
| | |||
* [[Cortisol]] | |||
* [[Aldosterone]] | |||
| | |||
* [[Vomiting]], [[volume depletion]], [[hyponatremia]], and [[hyperkalemia]] | |||
* 46-XY infants often show [[undervirilization]], due to a block in [[testosterone]] synthesis | |||
|- | |||
! Gestational [[hyperandrogenism]] | |||
| colspan="2" | | |||
* High maternal serum [[androgen]] concentrations (usually [[testosterone]] and [[androstenedione]]) | |||
* If [[virilization]] is caused by exogenous hormone administration, the values may be low because the offending hormone is usually a synthetic [[steroid]] not measured in assays for [[testosterone]] or other [[androgens]] | |||
| | |||
* [[Androgen]] excess in mother | |||
* History of [[androgen]] containing [[medication]] consumption during [[pregnancy]] in mother | |||
* [[Virilization]] in a 46,XX individual with normal female internal anatomy | |||
* Causes include maternal [[luteoma]] or theca-[[lutein]] [[cysts]], and [[placental]] [[aromatase]] enzyme deficiency | |||
|} | |||
=== [[17 alpha-hydroxylase deficiency]] can cause low reninemic [[hypertension]] and should be differentiate from other causes of [[pseudohyperaldosteronism]] (low renin): === | |||
{| class="wikitable" | |||
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Pseudohyperaldosteronism causes | |||
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease | |||
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Etiology | |||
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Clinical features | |||
! colspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Labratory | |||
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Treatment | |||
|- | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Elevated mineralocorticoid | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Renin | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Aldosterone | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Other | |||
|- | |||
| rowspan="9" |Endogenous causes | |||
![[17 alpha-hydroxylase deficiency]] | |||
| | |||
* Mutations in the [[CYP17A1]] gene | |||
| | |||
* [[Ambiguous genitalia]] in male | |||
* [[Hypertension]] | |||
* [[Primary amenorrhea]] | |||
* Absence of [[secondary sexual characteristics]] | |||
* Minimal [[body hair]] | |||
| rowspan="2" |[[Deoxycorticosterone]] ([[Deoxycorticosterone|DOC]]) | |||
| rowspan="2" |↓ | |||
| rowspan="2" |↓ | |||
|[[Cortisol]] ↓ | |||
| rowspan="2" |[[Corticosteroids]] | |||
|- | |||
![[11β-hydroxylase deficiency]] | |||
| | |||
* Mutations in the [[CYP11B1]] gene | |||
| | |||
* [[Ambiguous genitalia]] in female | |||
* [[Hypertension]] and [[hypokalemia]] | |||
* [[Virilization]] | |||
|[[Cortisol]] ↓ | |||
|- | |||
!Apparent mineralocorticoid excess syndrome (AME) | |||
|Genetic or acquired defect of 11-HSD gene | |||
* [[Cortisone]] decreases and [[cortisol]] accumulates and binds to [[aldosterone]] receptors | |||
| | |||
* Severe juvenile [[hypertension]] | |||
* [[Hypercalciuria]], [[nephrocalcinosis]], [[polyuria]] (due to [[hypokalemia]]-induced [[nephrogenic diabetes insipidus]]) | |||
* [[Renal failure]] | |||
|[[Cortisol]] has [[mineralocorticoid]] effects | |||
|↓ | |||
|↓ | |||
|Urinary free [[cortisone]] ↓↓ | |||
|[[Dexamethasone]] and/or [[mineralocorticoid]] blockers | |||
|- | |||
![[Liddle's syndrome|Liddle’s syndrome]] (Pseudohyperaldosteronism type 1) | |||
| | |||
* Mutation of the epithelial [[sodium]] channels ([[ENaC]]) [[gene]] in the distal [[renal tubules]] | |||
| | |||
* [[Hypertension]] | |||
* [[Hypokalemia]] | |||
|No extra [[mineralocorticoid]] presents, and mutations in [[Sodium|Na]] channels mimic [[aldosterone]] mechanism | |||
|↓ | |||
|↓ | |||
|[[Cortisol]] ↓ | |||
|[[Amiloride]] or [[triamterene]] | |||
|- | |||
![[Cushing’s syndrome]] | |||
| | |||
* Excess [[cortisol]] which saturates 11-HSD2 activity | |||
* Allows [[cortisol]] to bind [[mineralocorticoid receptor]] | |||
|Rapid [[Obesity|weight gain]], particularly of the [[trunk]] and [[face]] with [[limbs]] sparing ([[central obesity]]) | |||
* Proximal [[muscle weakness]] | |||
* A [[round face]] often referred to as a[[moon face|"moon face]]" | |||
* Excess [[sweating]] | |||
* [[Headache]] | |||
|[[Cortisol]] has [[mineralocorticoid]] effects | |||
|↓ | |||
| | |||
* ↓ if excess [[cortisol]] saturates 11-HSD2 enzyme activity | |||
* ↑ in direct activation of [[renin]] [[angiotensin]] system activation by [[glucocorticoids]] | |||
|Urinary free [[cortisol]] markedly ↑↑ | |||
| | |||
* [[Pasireotide]], [[Cabergoline]], [[Ketoconazole]], and [[Metyrapone]] | |||
* Adrenalectomy | |||
|- | |||
!Insensitivity to [[glucocorticoids]] (Chrousos syndrome) | |||
| | |||
* Mutations in [[glucocorticoid receptor]] (GR) gene | |||
| | |||
* [[Hypertension]] | |||
* Adrenal [[hyperandrogenism]] | |||
|[[Deoxycorticosterone]] ([[Deoxycorticosterone|DOC]]) | |||
|↓ | |||
|↓ | |||
|[[Cortisol]] | |||
|[[Dexamethasone]] | |||
|- | |||
![[Cortisol]]-secreting adrenocortical [[carcinoma]] | |||
| | |||
* Multifactorial | |||
| | |||
Rapid [[Obesity|weight gain]], particularly of the [[trunk]] and [[face]] with [[limbs]] sparing ([[central obesity]]) | |||
* Proximal [[muscle weakness]] | |||
* A [[round face]] often referred to as a "[[moon face]]" | |||
* Excess [[sweating]] | |||
* [[Headache]] | |||
|[[Cortisol]] has [[mineralocorticoid]] effects | |||
|↓ | |||
| | |||
* ↓ if excess [[cortisol]] saturates 11-HSD2 enzyme activity | |||
* ↑ in direct activation of [[renin]] [[angiotensin]] system activation by [[glucocorticoids]] | |||
|Urinary free [[cortisol]] markedly ↑↑ | |||
|[[Surgery]] | |||
|- | |||
!Geller’s syndrome | |||
| | |||
* [[Mutation]] of [[mineralocorticoid]] (MR) receptor that alters its specificity and allows [[progesterone]] to bind MR | |||
| | |||
* Severe [[hypertension]] particularly during [[pregnancy]] | |||
|[[Progesterone]] has [[mineralocorticoid]] effects | |||
|↓ | |||
|↓ | |||
| - | |||
|[[Mineralocorticoid]] blockers | |||
|- | |||
!Gordon’s syndrome (Pseudohypoaldosteronism type 2) | |||
| | |||
* Mutations of at least four genes have been identified, including WNK1 and WNK4 | |||
| | |||
* [[Hypertension]] | |||
* [[Hyperkalemia]] | |||
* Normal renal function | |||
|No excess [[mineralocorticoid]]; an increased activity of the [[thiazide]]-sensitive Na–Cl co-transporter in the [[distal tubule]] | |||
|↓ | |||
|Normal | |||
|[[Hyperkalemia]] | |||
|Thiazide diuretics and/or dietary sodium restriction | |||
|- | |||
| rowspan="4" |Exogenous causes | |||
!Corticosteroids with mineralocorticoid activity | |||
| | |||
* Fludrocortisone or fluoroprednisolone can mimic the action of aldosterone | |||
| | |||
* [[Hypertension]] | |||
* [[Hypokalemia]] | |||
|Medications such as fludrocortisone | |||
|↓ | |||
|↓ | |||
| - | |||
|Change the treatment | |||
|- | |||
!Licorice ingestion | |||
| | |||
* [[Glycyrrhetinic acid]] that binds [[mineralocorticoid]] receptor and blocks 11-HSD2 at the level of classical target tissues of [[aldosterone]] | |||
| | |||
* [[Hypertension]] | |||
* [[Hypokalemia]] | |||
|<nowiki>-</nowiki> | |||
|↓ | |||
|↓ | |||
|Moderate ↑ in urinary free cortisol | |||
|Discontinue licorice | |||
|- | |||
!Grapefruit | |||
| | |||
* High assumption of naringenin, a component of grapefruit, can also block 11-HSD (11β-hydroxysteroid dehydrogenase) | |||
| | |||
* [[Hypertension]] | |||
| - | |||
|↓ | |||
|↓ | |||
| - | |||
|Discontinue grapefruit | |||
|- | |||
![[Estrogens]] | |||
|[[Estrogens]] can retain [[sodium]] and water by different mechanisms, causing: | |||
* Increased [[blood pressure]] values and suppressing the [[renin]] [[aldosterone]] system, on the other side inducing [[secondary hyperaldosteronism]] due to the stimulation of the synthesis of [[angiotensinogen]] | |||
| | |||
* [[Hypertension]] | |||
* [[Headache]] | |||
* [[Edema]] | |||
* [[Weight gain]] | |||
|<nowiki>-</nowiki> | |||
|↓ | |||
|↓ | |||
| - | |||
|Discontinue [[estrogens]] | |||
|} | |} | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} |
Latest revision as of 11:52, 23 October 2017
17 alpha-hydroxylase deficiency Microchapters |
Differentiating 17 alpha-hydroxylase deficiency from other Diseases |
Diagnosis |
Treatment |
Case Studies |
17 alpha-hydroxylase deficiency differential diagnosis On the Web |
American Roentgen Ray Society Images of 17 alpha-hydroxylase deficiency differential diagnosis |
FDA on 17 alpha-hydroxylase deficiency differential diagnosis |
CDC on 17 alpha-hydroxylase deficiency differential diagnosis |
17 alpha-hydroxylase deficiency differential diagnosis in the news |
Blogs on 17 alpha-hydroxylase deficiency differential diagnosis |
Risk calculators and risk factors for 17 alpha-hydroxylase deficiency differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mehrian Jafarizade, M.D [2]
Overview
17 alpha-hydroxylase deficiency must be differentiated from diseases that present with primary amenorrhea and female external genitalia such as pregnancy, androgen insensitivity syndrome, 3beta-hydroxysteroid dehydrogenase type 2 deficiency, gonadal dysgenesis, testicular regression syndrome, LH receptor defects, 5-alpha-reductase type 2 deficiency, mullerian agenesis, primary ovarian insufficiency, hypogonadotropic hypogonadism and turner syndrome.
Differentiating 17 alpha-hydroxylase deficiency from other Diseases
17 alpha-hydroxylase deficiency must be differentiated from diseases that present with primary amenorrhea and female external genitalia such as pregnancy, androgen insensitivity syndrome, 3beta-hydroxysteroid dehydrogenase type 2 deficiency, gonadal dysgenesis, testicular regression syndrome, LH receptor defects, 5-alpha-reductase type 2 deficiency, mullerian agenesis, primary ovarian insufficiency, hypogonadotropic hypogonadism and turner syndrome. .[1][2][3][4][5][6][7][8]
Differential diagnosis for primary amenorrhea:
Disease name | Cause | Differentiating | ||||||
---|---|---|---|---|---|---|---|---|
Findings | Uterus | Breast development | Testosterone | LH | FSH | Karyotyping | ||
17-alpha-hydroxylase deficiency |
|
No |
No |
↓ |
Normal |
Normal |
||
3 beta-hydroxysteroid dehydrogenase deficiency |
|
Yes in female |
Yes in female |
↓ |
Normal |
Normal |
||
Gonadal dysgenesis |
|
|
Yes |
Yes |
↓ |
↑ |
↑ |
|
Testicular regression syndrome |
|
|
No |
No |
↓ |
↑ |
↑ |
|
LH receptor defects |
|
No |
No |
↓ |
↑ |
↑ |
||
5-alpha-reductase type 2 deficiency |
|
No |
No |
Normal male range |
High to normal |
High to normal |
||
Androgen insensitivity syndrome |
|
|
No |
Yes |
Normal male range |
Normal |
Normal |
|
Mullerian agenesis |
|
No |
Yes |
Normal female range |
Normal |
Normal |
||
Primary ovarian insufficiency |
|
|
Yes |
Yes |
Normal female range |
↑ |
↑ |
|
Hypogonadotropic hypogonadism |
|
|
Yes |
No |
Normal female range |
Low |
Normal |
|
|
|
Yes |
Yes |
Normal female range |
↑ |
↑ |
17 alpha-hydroxylase deficiency must be differentiated from diseases that cause ambiguous genitalia:[9][10]
Disease name | Steroid status | Important clinical findings | |
---|---|---|---|
Increased | Decreased | ||
17-α hydroxylase deficiency |
| ||
Classic type of 21-hydroxylase deficiency |
|
| |
11-β hydroxylase deficiency |
|
| |
3 beta-hydroxysteroid dehydrogenase deficiency |
| ||
Gestational hyperandrogenism |
|
|
17 alpha-hydroxylase deficiency can cause low reninemic hypertension and should be differentiate from other causes of pseudohyperaldosteronism (low renin):
Pseudohyperaldosteronism causes | Disease | Etiology | Clinical features | Labratory | Treatment | |||
---|---|---|---|---|---|---|---|---|
Elevated mineralocorticoid | Renin | Aldosterone | Other | |||||
Endogenous causes | 17 alpha-hydroxylase deficiency |
|
|
Deoxycorticosterone (DOC) | ↓ | ↓ | Cortisol ↓ | Corticosteroids |
11β-hydroxylase deficiency |
|
|
Cortisol ↓ | |||||
Apparent mineralocorticoid excess syndrome (AME) | Genetic or acquired defect of 11-HSD gene
|
|
Cortisol has mineralocorticoid effects | ↓ | ↓ | Urinary free cortisone ↓↓ | Dexamethasone and/or mineralocorticoid blockers | |
Liddle’s syndrome (Pseudohyperaldosteronism type 1) |
|
No extra mineralocorticoid presents, and mutations in Na channels mimic aldosterone mechanism | ↓ | ↓ | Cortisol ↓ | Amiloride or triamterene | ||
Cushing’s syndrome |
|
Rapid weight gain, particularly of the trunk and face with limbs sparing (central obesity)
|
Cortisol has mineralocorticoid effects | ↓ |
|
Urinary free cortisol markedly ↑↑ |
| |
Insensitivity to glucocorticoids (Chrousos syndrome) |
|
|
Deoxycorticosterone (DOC) | ↓ | ↓ | Cortisol | Dexamethasone | |
Cortisol-secreting adrenocortical carcinoma |
|
Rapid weight gain, particularly of the trunk and face with limbs sparing (central obesity)
|
Cortisol has mineralocorticoid effects | ↓ |
|
Urinary free cortisol markedly ↑↑ | Surgery | |
Geller’s syndrome |
|
|
Progesterone has mineralocorticoid effects | ↓ | ↓ | - | Mineralocorticoid blockers | |
Gordon’s syndrome (Pseudohypoaldosteronism type 2) |
|
|
No excess mineralocorticoid; an increased activity of the thiazide-sensitive Na–Cl co-transporter in the distal tubule | ↓ | Normal | Hyperkalemia | Thiazide diuretics and/or dietary sodium restriction | |
Exogenous causes | Corticosteroids with mineralocorticoid activity |
|
Medications such as fludrocortisone | ↓ | ↓ | - | Change the treatment | |
Licorice ingestion |
|
- | ↓ | ↓ | Moderate ↑ in urinary free cortisol | Discontinue licorice | ||
Grapefruit |
|
- | ↓ | ↓ | - | Discontinue grapefruit | ||
Estrogens | Estrogens can retain sodium and water by different mechanisms, causing:
|
- | ↓ | ↓ | - | Discontinue estrogens |
References
- ↑ Maimoun L, Philibert P, Cammas B, Audran F, Bouchard P, Fenichel P, Cartigny M, Pienkowski C, Polak M, Skordis N, Mazen I, Ocal G, Berberoglu M, Reynaud R, Baumann C, Cabrol S, Simon D, Kayemba-Kay's K, De Kerdanet M, Kurtz F, Leheup B, Heinrichs C, Tenoutasse S, Van Vliet G, Grüters A, Eunice M, Ammini AC, Hafez M, Hochberg Z, Einaudi S, Al Mawlawi H, Nuñez CJ, Servant N, Lumbroso S, Paris F, Sultan C (2011). "Phenotypical, biological, and molecular heterogeneity of 5α-reductase deficiency: an extensive international experience of 55 patients". J. Clin. Endocrinol. Metab. 96 (2): 296–307. doi:10.1210/jc.2010-1024. PMID 21147889.
- ↑ Moreira AC, Leal AM, Castro M (1990). "Characterization of adrenocorticotropin secretion in a patient with 17 alpha-hydroxylase deficiency". J. Clin. Endocrinol. Metab. 71 (1): 86–91. doi:10.1210/jcem-71-1-86. PMID 2164530.
- ↑ Heremans GF, Moolenaar AJ, van Gelderen HH (1976). "Female phenotype in a male child due to 17-alpha-hydroxylase deficiency". Arch. Dis. Child. 51 (9): 721–3. PMC 1546244. PMID 999330.
- ↑ Biglieri EG (1979). "Mechanisms establishing the mineralocorticoid hormone patterns in the 17 alpha-hydroxylase deficiency syndrome". J. Steroid Biochem. 11 (1B): 653–7. PMID 226795.
- ↑ Saenger P (1996). "Turner's syndrome". N. Engl. J. Med. 335 (23): 1749–54. doi:10.1056/NEJM199612053352307. PMID 8929268.
- ↑ Bastian C, Muller JB, Lortat-Jacob S, Nihoul-Fékété C, Bignon-Topalovic J, McElreavey K, Bashamboo A, Brauner R (2015). "Genetic mutations and somatic anomalies in association with 46,XY gonadal dysgenesis". Fertil. Steril. 103 (5): 1297–304. doi:10.1016/j.fertnstert.2015.01.043. PMID 25813279.
- ↑ Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE (1974). "Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism". Science. 186 (4170): 1213–5. PMID 4432067.
- ↑ Schnitzer JJ, Donahoe PK (2001). "Surgical treatment of congenital adrenal hyperplasia". Endocrinol. Metab. Clin. North Am. 30 (1): 137–54. PMID 11344932.
- ↑ Hughes IA, Nihoul-Fékété C, Thomas B, Cohen-Kettenis PT (2007). "Consequences of the ESPE/LWPES guidelines for diagnosis and treatment of disorders of sex development". Best Pract. Res. Clin. Endocrinol. Metab. 21 (3): 351–65. doi:10.1016/j.beem.2007.06.003. PMID 17875484.
- ↑ White PC, Speiser PW (2000). "Congenital adrenal hyperplasia due to 21-hydroxylase deficiency". Endocr. Rev. 21 (3): 245–91. doi:10.1210/edrv.21.3.0398. PMID 10857554.